Roots Analysis

APRIL 15, 2024

These complex entities, such as antibodies, antibody drug conjugates, cell therapies, gene therapies, and therapeutic proteins, are highly specific molecules that are designed to precisely target biomarkers associated with a particular disease pathway.

Manufacturing 40

Manufacturing Production Contract Manufacturing Contamination 40

Roots Analysis

MAY 24, 2024

These autoinjectors offer several advantages, including simplified drug administration process, safer injection, reduced risk of contamination and minimized maintenance ( due to elimination of cleaning and sterilization steps ). This is extremely important for injectable medications.

Drug Delivery 40

Drug Delivery Containment Contamination Production 40

Roots Analysis

OCTOBER 24, 2023

The limitations of stainless-steel bioreactors such as high risk of contamination, process related challenges and high operational cost have prompted innovators to develop more advanced single use bioreactor in order to meet the rising demand for safe and efficacious biotherapeutics.

Manufacturing 40

Manufacturing Contamination Marketing Production 40

Roots Analysis

AUGUST 30, 2023

Further, in the same year, nearly half of the biologic approvals were allotted to novel class of modalities, including antibody drug conjugates (ADCs), bispecific antibodies, cell therapies and gene therapies.

Manufacturing 40

Manufacturing Production Contamination Antibody 40

Roots Analysis

JUNE 6, 2024

Some of the advantages include convenient usability, enhanced precision, improved sterility, reduced risk of microbial contamination, easy storage and disposal, as well as quick delivery in emergency situations. Reduced Medication Errors: As the autoinjectors contain the exact dose of medication, they enable reduced dosing errors.

Medicine 40

Medicine Drug Delivery Manufacturing Marketing 40

The Pharma Data

FEBRUARY 18, 2022

In partnership with local quality control testing labs, BioNTech will help to ensure the identity, composition, strength, purity, absence of product- and process-related impurities, as well as the absence of microbiological contamination of each produced batch. The first BioNTainer is expected to arrive in Africa in the second half of 2022.

Manufacturing 40

Manufacturing Vaccination Vaccine Production 40

XTalks

MAY 29, 2024

In its acquisitions, J&J also acquired antibody-drug conjugate (ADC) developer Ambryx and cardiac med tech Laminar along with more than 50 smaller, early-stage licensing deals and partnerships. billion to acquire Telavant for an anti-TL1A antibody, an inflammatory bowel disease candidate ready for Phase III trials.

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccine 52

XTalks

NOVEMBER 7, 2022

Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. However, Dr. Bahassi reported that the selection of CTCs using this method is often not very efficient and the CTC population is usually highly contaminated with leukocytes.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

MAY 4, 2021

Biosimilars, which grew 79% operationally to $530 million, primarily driven by recent oncology monoclonal antibody biosimilar launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab) globally, as well as continued growth from Retacrit (epoetin) in the U.S.;

Vaccination 40

Vaccination Vaccine Production Sales 40

XTalks

OCTOBER 16, 2020

Inmazeb is a combination of three different antiviral monoclonal antibodies. Ebola virus is transmitted through direct contact with blood, body fluids and tissues of infected people or wild animals, as well as with surfaces and materials – such as bedding and clothing – contaminated with these fluids. Targeted Antiviral Treatment.

Antibody 98

Antibody Drugs Clinical Trials Clinical Trials 98

Pharmaceutical Technology

APRIL 27, 2023

Every stage of development should result in a reproducible, safe drug product with no cross contamination from one batch to another. Almost 20 years later, the benefits of SUT are well recognised in the manufacture of monoclonal antibodies and biopharmaceutical manufacturing in general.

Manufacturing 130

Manufacturing RNA Contamination Vaccination 130

Pharmaceutical Technology

MAY 17, 2023

Recombinant Insulin’s role is well established in monoclonal antibody manufacturing processes, but its current applications and future potential do not stop there. One big challenge is contamination. As with contamination, variation in outcomes and product quality are often a result of the raw materials used.

Insulin 130

Insulin Production Manufacturing Contamination 130

Pharmaceutical Technology

APRIL 16, 2023

Yet PFSs also come with a challenge such as presenting difficulties in maintaining the stability of protein-based molecules or complex monoclonal antibodies. Conventional cartridge-based solutions are complex and require users to manually attach the needle to the device, risking contamination and injuries. SHL Medical’s Molly 2.25

Protein 130

Protein Containment Drug Delivery Drugs 130

Pharmaceutical Technology

JANUARY 12, 2023

PM: Lyophilization is widely used in the pharmaceutical and biotech industry for small molecule drug products, vaccines, antibodies, and other biological material. What are the key advantages of this stabilization method? Free eBook. Manufacturing of Cytotoxic and Non-Cytotoxic Drugs in a Multiproduct Facility. United Kingdom. United States.

Production 130

Production Contamination Development Manufacturing 130

XTalks

MARCH 11, 2025

Emerging evidence indicates that a multivalent mRNA vaccine encoding hemagglutinin antigens from all known influenza virus subtypes can elicit broad, cross-reactive antibody responses in animal models, demonstrating the potential of mRNA platforms to overcome challenges posed by antigenically variable viruses.

Vaccination 64

Vaccination Vaccine Development Manufacturing 64

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.

Vaccine 92

Vaccine Vaccination Antibody Life Science 92